Cellular and Molecular Pathology of Prostate Cancer Precursors

REFERENCES

• McNeal JE, Bostwick DG. Intraductal dysplasia: A premalignant lesion of the prostate. Hum Pathol 1986; 17: 64–71.
   PubMed Web of Science ®Google Scholar
• Bostwick DG. High grade prostatic intraepithelial neoplasia: The most likely precursor of prostate cancer. Cancer 1995; 75: 1823–36.
   Web of Science ®Google Scholar
• Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 1996; 29: 117–34.
   Google Scholar
• Qian J, Wollan P. Bostwick DG. The extent and multicentricity of high grade intraepithial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol 1997; 28: 143–8.
   Google Scholar
• Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, et al. Allelic loss on chromosome 8p12-21 in microdissected prostatic intra-epithelial neoplasia. Cancer Res 1995; 55: 2959–62.
   Google Scholar
• Sakr WA, Macoska JA, Benson PD, Grignon DJ, Wolman SR, Pontes JE, et al. Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 1994; 54: 3273–9.
   PubMed Web of Science ®Google Scholar
• Qian JQ, Bostwick DG, Takahashi S, Borell TJ, Herath if, Lieber MM, et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma de-tected by fluorescence in situ hybridization. Cancer Res 1995; 55: 5408–14.
   PubMed Web of Science ®Google Scholar
• Cunningham IM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, et al. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996; 56: 4475–82.
   PubMed Web of Science ®Google Scholar
• Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carci-noma by fluorescence in situ hybridization (FISH). Cancer Res 1997; 57: 524–31.
   PubMed Web of Science ®Google Scholar
• Bostwick DG. Prospective origins of prostate carcino-ma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 1996; 78: 330–6.
   Google Scholar
• Nagle RB, Brawer MK, Kittelson J, Clark V. Pheno-typic relationship of prostatic intraepithelial neoplasia to invasive prostatic carcinoma. Am J Pathol 1991; 138: 119–28.
   PubMed Web of Science ®Google Scholar
• Wemert N, Seitz G. Immunohistochemical investiga-tion in different cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in prostate carcinoma. Pathol Res Pract 1987; 182: 617–26.
   PubMed Web of Science ®Google Scholar
• Xue Y, Smedts F, Debruyne FM, de la Rosette JJ, Schalken JA. Identification of intermediate cell types of keratin expression in the developing human prostate. Prostate 1998; 34: 292–301.
   Google Scholar
• Di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnosis, prognostic and therapeutic implications. Cancer 1992; 70: 254–68.
   Google Scholar
• Di Sant'Agnese PA, Cockett AT. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996; 15: 357–61.
   Web of Science ®Google Scholar
• Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue. Morphogenesis, proliferation and androgen receptor status. Prostate 1998; 8: 18–22.
   Google Scholar
• Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996; 28: 98–106.
   PubMed Web of Science ®Google Scholar
• Bonkhoff H. Role of the basal cells in premalignant changes of the human prostate: A stem cell concept for the development of prostate cancer. Eur Urol 1996; 30: 201–5.
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Remberger K. Morphogenetic concepts of normal and abnormal growth of the human prostate. Virchows Arch 1998; 433: 195–202.
   PubMed Web of Science ®Google Scholar
• Foster CS, Ke Y. Stem cells in prostatie epithelia. Int J Exp Pathol 1997; 78: 311–29.
   PubMed Web of Science ®Google Scholar
• Pierce GB. Neoplasms, differentiation and mutations. Am J Pathol 1974; 77: 103–18.
   PubMed Web of Science ®Google Scholar
• Pollen CS, Loeffler M. Stem cells: attributes, cycle, spirals, pitfalls and uncertainties. Lessons for and from the crypt. Development 1990; 110: 1001–20.
   Google Scholar
• Verhagen AP, Aalders TW, Ramaekers FC, Debruyne FM, Sehalken JA. Differential expression of keratins in the basal and luminal compartments of rat prostatie epithelium during degeneration and regeneration. Prostate 1988; 13: 25–38.
   Google Scholar
• De Marzo AM, Nelson WG, Meeker AK, Coffey DS. Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998; 160: 2381–92.
   PubMed Web of Science ®Google Scholar
• De Marzo AM, Marehi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatie eareinogenesis. Am J Pathol 1999; 155: 1985–92.
   PubMed Web of Science ®Google Scholar
• Verhagen AP. Colocalization of basal and luminal cell-type eytokeratins in human prostate cancer. Cancer Res 1992; 52: 6182–7.
   PubMed Web of Science ®Google Scholar
• Van der Kwast TH, Tetu B, Suburu ER, Gomez J, Iemay M, Labrie F. Cycling activity of benign prostatie epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. J Pathol 1998; 186: 406–9.
   PubMed Web of Science ®Google Scholar
• Van der Kwast TH, Labrie F, Tetu B. Prostatie intraepithelial neoplasia and endocrine manipulation. Eur Urol 1999; 35: 508–10.
   PubMed Web of Science ®Google Scholar
• Montironi R, Magi-Galluzzi C, Fabris G. Apoptotie bodies in prostatie intraepithelial neoplasia and pro-static adenocareinoma following total androgen abla-tion. Pathol Res Praet 1995; 191: 873–80.
   PubMed Web of Science ®Google Scholar
• Evans GS, Chandler JA. Cell proliferation studies in the rat prostate: The effects of castration and androgen-induced regeneration upon basal and secretory cell proliferation. Prostate 1987; 4: 339–51.
   Web of Science ®Google Scholar
• Van der Kwast TH, Labrie F, Tetu B. Persistence of high-grade prostatie intra-epithelial neoplasia under combined androgen blockade therapy. Hum Pathol 1999; 30: 1503–7.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, et al. Independent origin of multiple foci of prostatie intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 1998; 83: 1995–2002.
   PubMed Web of Science ®Google Scholar
• Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatie eareinogenesis. Proe Natl Aead Sei USA 1994; 91: 11733–7.
   PubMed Web of Science ®Google Scholar
• Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, et al. Development, progres-sion, and androgen-dependence of prostate tumors in probasin-large T antigen transgenie mice: a model for prostate cancer. Lab Invest 1998; 78: 319–33.
   PubMed Web of Science ®Google Scholar
• Cheng L, Shan A, Cheville JC, Qian J, Bostwick DG. Atypical adenomatous hyperplasia of the prostate: a premalignant lesion? Cancer Res 1998; 58: 389–91.
   Google Scholar
• Myers RB, Grizzle WE. Biomarker expression in prostatie intraepithelial neoplasia. Eur Urol 1996; 30: 153–66.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Amin MB, Dundore P, Marsh W, Schultz DS. Architectural patterns of high grade Scand J Urol Nephrol Suppl 205 prostatie intraepithelial neoplasia. Hum Pathol 1993; 24: 298–310.
   Google Scholar
• Bonkhoff H, Stein U, Remberger K. The proliferative function of basal cells in the normal and hyperplastie human prostate. Prostate 1994; 24: 114–8.
   Google Scholar
• Ware JL. Prostate cancer progression. Implications of histopathology. Am J Pathol 1994; 145: 893–993.
   Web of Science ®Google Scholar
• Bonkhoff H, Fixemer T, Remberger K. Relation between Bel-2, cell proliferation and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1998; 34: 251–8.
   Google Scholar
• Bonkhoff H, Fisemer T, Hunsieker I, Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatie lesions. Am J Pathol 1999; 155: 641–7.
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Stein U, Welter C, Remberger K. Differential expression of the pS2 protein in the human prostate cancer: association with premalignant changes and neuroendoerine differentiation. Hum Pathol 1995; 26: 824–8.
   PubMed Web of Science ®Google Scholar
• Montironi R, Bostwick DG, Bonkhoff H, Coekett A, Helpap B, Troneoso P. et al. Origins of prostate cancer. Cancer 1996; 78: 362–5.
   PubMed Web of Science ®Google Scholar
• Janssen PJ, Brinkmann AO, Boersma WJ, Van der Kwast TH. Immunohistochemical detection of the androgen receptor with monoclonal antibody F39.4 in routinely processed, paraffin-embedded human tissues after microwave pre-treatment. J Histoehem Cytoehem 1994; 42: 1169–75.
   Google Scholar
• Bonkhoff H, Stein U, Remberger K. Multidirectional differentiation in the normal, hyperplastie and neo-plastic human prostate: Simultaneous demonstration of cell specific epithelial markers. Hum Pathol 1994; 25: 42–6.
   Google Scholar
• Bonkhoff H. Analytical molecular pathology of epithelial-stromal interactions in the normal and neoplastie prostate. Anal Quant Cytol Histol 1998; 20: 437–42.
   PubMed Web of Science ®Google Scholar
• Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL, et al. Differential expression of extraeellular matrix molecules and the alpha 6-integrins in the normal and neoplastie prostate. Am J Pathol 1994; 145: 167–74.
   PubMed Web of Science ®Google Scholar
• Nagle RB, Hao J, Knox JD, Dalkin BL, Clark V, Cress AE. Expression of hemidesmosomal and extraeellular matrix proteins by normal and malignant human prostate tissue. Am J Pathol 1995; 146: 1498–507.
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Stein U, Remberger K. Differential expression of -6 and -2 very late antigen integrins in the normal, hyperplastie and neoplastie human pros-tate. Simultaneous demonstration of cell surface receptors and their extraeellular ligands. Hum Pathol 1993; 24: 243–8.
   Google Scholar
• Bonkhoff H, Wemert N, Dhom G, Remberger K. Distribution of basement membranes in primary and metastatic carcinomas of the prostate. Hum Pathol 1992; 23: 934–9.
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Wemert N, Dhom G, Remberger K. Basement membranes in fetal, adult normal, hyper-plastic and neoplastie human prostate. Virehows Arch A: Pathol 1991; 418: 375–81.
   Web of Science ®Google Scholar
• Phler C, Fixemer T, Jung V, Dooley S, Remberger K, Bonkhoff H. In situ analysis of genes coding collagen IV al chain, laminin bl chain, and 5-laminin in prostate tissue and prostate cancer. Increased basement membrane gene expression in metastatic lesions. Prostate 1998; 36: 143–50.
   Google Scholar
• Macoska JA, Micale MA, Sakr WA, Benson PD, Wolman SR. Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis. Genes Chromosomes Cancer 1993; 8: 88–97.
   Google Scholar
• Trapman J, Sleddens HF, van-der-Weiden MM, Dinjens WN, Konig JJ, Schroder FH, et al. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8587. Cancer Res 1994; 54: 6061–4.
   Google Scholar
• Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, et al. Allelic loss of chromosome 16q and chromosome 10q in human prostate cancer. Proc Natl Acad Sci USA 1990; 87: 8751–5.
   PubMed Web of Science ®Google Scholar
• Zenldusen JC, Thompson JC, Troncoso P. Kagan J, Conti CJ. Loss of heterozygosity in human primary prostate carcinoma: A possible tumor suppressor gene at 7q31.1. Cancer Res 1994; 54: 6370–3.
   Google Scholar
• Ittmann MM. Loss of heterozygosity on chromosome 10 and 17 in clinically localized prostate carcinoma. Prostate 1996; 28: 275–81.
   PubMed Web of Science ®Google Scholar
• Ittmann MM, Wieczorek R. Alterations of the retino-blastoma gene in clinically localized, stage B prostate adenocarcinoma. Hum Pathol 1996; 27: 28–34.
   PubMed Web of Science ®Google Scholar
• Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ. Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 1996; 56: 1142–5.
   PubMed Web of Science ®Google Scholar
• Gao X, Zacharek A, Salkowski A, Grignon DJ, Sakr W, Porter AT, et al. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995; 55: 1002–5.
   PubMed Web of Science ®Google Scholar
• Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung H-J, Dawson DV, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998; 90: 233–7.
   PubMed Web of Science ®Google Scholar
• Bandyk MG, Zhao L, Troncoso P. Pisters LL, Palmer JL, Voneschenbach AC, et al. A potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer 1994; 9: 19–27.
   Google Scholar
• Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, et al. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization. Cancer 1994; 54: 3574–9.
   Web of Science ®Google Scholar
• Latil A, Baron JC, Cussenot O, Fournier G, Soussi T, Boccon-Gibod L, et al. Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q. Genes Chromo-somes Cancer 1994; 11: 119–25.
   Google Scholar
• Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, et al. Analysis of 99 micro-disected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 1996; 56: 2411–6.
   PubMed Web of Science ®Google Scholar
• Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH. Mapping of regions of physical deletion on chromo-some 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol 1995; 153: 249–54.
   Google Scholar
• Alers CA, Krijtenburg PJ, Vissers KJ, Bosman FT, van der Kwast TH, Dekken H. Interphase etyogenetics of prostatic adenocarcinoma and precursor lesions: ana-lysis of 25 radical prostatectomies and 17 adjacent prostatic intraepithelial neoplasms. Genes Chromo-somes Cancer 1995; 12: 241–50.
   Google Scholar
• Alcaraz A, Takahashi S, Brown JA, Herath IF, Bergstralh E, Larson-Keller J, et al. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 1994; 54: 3998–4002.
   Google Scholar
• Brown JA, Alcaraz A, Takahashi S, Persons DL, Lieber MM, Jenkins RB. Chromosomal aneusomies detected by fluorescence in situ hybridization analysis in clinically localized prostate carcinoma. J Urol 1994; 152: 1157–62.
   PubMed Web of Science ®Google Scholar
• Dahiya R, McCarville H, Hu WX, Lee C, Chui RM, Kaur G, et al. Chromosome 3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma. Int J Cancer 1997; 71: 20–5.
   PubMed Web of Science ®Google Scholar
• Latil A, Cussenot O, Fournier G, Baron JC, Lidereau R. Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. Clin Cancer Res 1995; 1: 1385–9.
   PubMed Web of Science ®Google Scholar
• Latil A, Fournier G, Cussenot O, Lidereau R. Differen-tial chromosome allelic imbalance in the progression of human prostate cancer. J Urol 1996; 156: 2079–83.
   PubMed Web of Science ®Google Scholar
• Cooney KA, Wetzel JC, Consolino CM, Wojno KJ. Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 1996; 56: 4150–3.
   PubMed Web of Science ®Google Scholar
• Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino PT. A comparison of the morphological features of cancer arising in the transition zone and in the peri-pheral zone of the prostate. J Urol 1991; 146: 1069–76.
   Google Scholar
• Konishi N, Hiasa Y, Matsuda H, Tao M, Tsuzuki T, Hayashi I, et al. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am J Pathol 1995; 147: 1112–22.
   PubMed Web of Science ®Google Scholar
• Greene DR, Rogers E, Wessels EC, Wheeler TM, Taylor SR, Santucci RA, et al. Some small prostate cancers are nondiploid by nuclear image analysis: Correlation of deoxyribonucleic acid ploidy status and pathological features. J Urol 1994; 151: 1301–7.
   PubMed Web of Science ®Google Scholar
• Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Cancer 1993; 73: 2013–26.
   Google Scholar
• Brothman AR, Peehl DM, McNeal JE. Frequency and pattern of karyotypic anomalies in human prostate cancer. Cancer Res. 1990; 50: 3795–803.
   PubMed Web of Science ®Google Scholar
• Lundgren R, Mandahl N, Heim S, Limon J, Henrikson H, Mitelman F. Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes, Chromosomes and Cancer 1992; 4: 16–24.
   PubMed Web of Science ®Google Scholar
• Zitzelsberger H, Szucs S, Weier HU, Lehmann L, Braselmann H, Enders S, et al. Numerical abnormali-ties of chromosome 7 detected by fluorescence in situ hybridization (FISH) on paraffin-embedded tissue sections with centromere-specific DNA probes. J Pathol 1994; 172: 325–35.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Alcaraz A, Brown JA, Borell TJ, Herath JF, Bergstralj EJ, et al. Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridisation are prognostic markers for pathologic stage C (pT3N0M0) prostate carcinoma. Clin Cancer Res 1996; 2: 137–45.
   PubMed Web of Science ®Google Scholar
• Zenklusen JC, Bieche I, Liereau R, Conti CJ. (C-A)„, microsatellite repeat D75522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci USA 1994b; 91: 12155–8.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Shan A, Ritland SR, Delacey K, Bostwick DG, Lieber MM, et al. Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer in association with tumor aggressiveness and progression. Cancer Res 1995; 55: 4114–9.
   Google Scholar
• Collard JG, van de Poll M, Seheffer A, Roos E, Hopman ABM, Geurts van Kessel ABM, et al. Location of genes involved in invasion and metastasis on human chromosome 7. Cancer Res 1987; 47: 6666–70.
   PubMed Web of Science ®Google Scholar
• Zenldusen JC, Thompson JC, Klein-Szanto AJP, Conti CJ. Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q331.1: Evidence for a broad range tumor suppressor gene. Cancer Res 1995; 55: 1347–50.
   Google Scholar
• Jenkins RB, Qian JC, Lee HK, Huang HJ, Hirasawa K, Bostwick DG, et al. A molecular cytogenetie analysis of 7q31 in prostate cancer. Cancer Res 1998; 58: 759–66.
   PubMed Web of Science ®Google Scholar
• Jenkins RB, Takahashi S. Delaeey KA, Bergstralh E, Lieber MM. Prognostic significance of allelic imbal-ance of chromosome arms 7q, 16q and 18q in stage T3MOMO prostate cancer. Genes Chromosomes Cancer 1998; 21: 131–43.
   Google Scholar
• Cheng L, Shan A, Qian J, Darson M, Thibodeaul SN, Jenkins RB, et al. Genetic heterogeneity in prostatie intraepithelial neoplasia and carcinoma. Mod Pathol 1998; 11: A78.
   Web of Science ®Google Scholar
• MaeGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R. Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosomes Cancer 1994; 10: 151–9.
   PubMed Web of Science ®Google Scholar
• Maeoska JA, Trybus TM, Benson PD, Sakr WA, Grifon DJ, Wojno KD, et al. Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res 1995; 55: 5390–5.
   PubMed Web of Science ®Google Scholar
• Maeoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, Powell IJ, et al. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res 1994; 54: 3824–30.
   PubMed Web of Science ®Google Scholar
• Bova GS, Carter BS, Bussemakers MJG, Emi M, Fujiwara Y, Kyprianou N, et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993; 53: 3869–73.
   PubMed Web of Science ®Google Scholar
• Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, et al. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomie hybridization and allelotyping. Cancer Res 1996; 56: 3091–102.
   PubMed Web of Science ®Google Scholar
• Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomie hybridization. Cancer Res 1995; 55: 342–7.
   PubMed Web of Science ®Google Scholar
• Van der Berg C, Guan XY, von Hoff D, Jenkins R, Bittner E, Griffin C, et al. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin Cancer Res 1995; 1: 11–8.
   PubMed Web of Science ®Google Scholar
• Paradis V, Dargere D, Laurendeau I, Benoit G, Vidaud M, Jardin A, et al. Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatie intraepithelial neoplasia, and normal prostate tissue. J Pathol 1999; 189: 213–8.
   PubMed Web of Science ®Google Scholar
• Koeneman KS, Pan CX, Jin JK, Pyle JM, Flanigan RC, Shankey TV, et al. Telomerase activity, telomere length and DNA ploidy in prostatie intraepithelial neoplasia (PIN). J Urol 1998; 160: 1533–9.
   PubMed Web of Science ®Google Scholar
• Zhang WB, Kapusta LR, Slingerland JM, Klotz LH. Telomerase activity in prostate cancer, prostatie intra-epithelial neoplasia and benign prostatie epithelium. Cancer Res 1998; 58: 619–21.
   PubMed Web of Science ®Google Scholar
• Krajewski M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, et al. Immunohistochemical analysis of bel-2, bax, bel-X and me-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567–76.
   PubMed Web of Science ®Google Scholar
• Colombel M, Symmans G, Gil S, O'Toole K, Chopin D, Benson M, et al. Detection of the apoptosis-suppressing oneoprotein bel-2 in hormone-refractory human prostate cancer. Am J Pathol 1993; 143: 390–400.
   Google Scholar
• Baltaei S, Orhan D, Ozer G, Tolunay O, Gogous O. Bel-2 proto-oneogene expression in low- and high-grade prostatie intraepithelial neoplasia. Br J Urol Int 2000; 85: 155–9.
   Google Scholar
• Erdamar S, Yang G, Harper JW, Lu X, Kahan MW, Thompson TC, et al. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod Pathol 1999; 12: 751–5.
   PubMed Web of Science ®Google Scholar
• Miet SM, Neyra M, Jaques R, Dubemard P. Revol AA, Mareais C. RER(±) phenotype in prostate intra-epithelial neoplasia associated with human prostate-carcinoma development. Int J Cancer 1999; 82: 635–9.
   PubMed Web of Science ®Google Scholar
• Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990; 17: 337–47.
   Google Scholar
• Cannon L, Bishop DT, Skolnick M, Hunt S, Lyon it, Smart CR. Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv 1982; 1: 47–69.
   Google Scholar
• Grönberg H, Damber L, Damber J-E. Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 1996; 77: 138–43.
   Google Scholar
• Woolf CM. An investigation of familial aspects of carcinoma of the prostate. Cancer 1960; 13: 739–44.
   PubMed Web of Science ®Google Scholar
• Krain LS. Some epidemiological variables in prostatie carcinoma in California. Prey Med 1974; 3: 154–9.
   PubMed Web of Science ®Google Scholar
• Meikle AW, Smith JA, West DW. Familial factors affecting prostatie cancer risk and plasma sex-steroid levels. Prostate 1985; 6: 121–8.
   Google Scholar
• Fineham SM, Hill GB, Hanson J, Wijayasinghe C. Epidemiology of prostatie cancer: a ease-control study. Prostate 1990; 17: 189–206.
   PubMed Web of Science ®Google Scholar
• Ghadirian P. Cadotte M, Lacroix A, Perret C. Family aggregation of cancer of the prostate in Quebec: the tip of the iceberg. Prostate 1991; 19: 43–52.
   Google Scholar
• Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR. Familial patterns of prostate cancer: a ease-control analysis. J Urol 1991; 146: 1305–7.
   Google Scholar
• Cannon-Albright LA, Thomas A, Goldgar DE, Ghola-mi K, Rowe K, Jacobsen M, et al. Familiarity of cancer in Utah. Cancer Res 1994; 54: 2378–85.
   PubMed Web of Science ®Google Scholar
• Goldgar DE, Easton DF, Cannon-Albright LA, Skol-nick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86: 1600–8.
   Google Scholar
• Aprikan AG, Bazinet M, Plante M, Meshref A, Trudel C, Aronson S, et al. Family history and the risk of prostatie carcinoma in a high risk group of urologieal patients. J Urol 1995; 154: 404–6.
   PubMed Web of Science ®Google Scholar
• Monroe KR, Yu MC, Kolonel LN, Coetzee GA, Wilkens LR, Ross RK, et al. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med 1995; 1: 827–9.
   PubMed Web of Science ®Google Scholar
• Narod SA, Dupont A, Cusan L, Diamond P, Gomez it, Suburu R, et al. The impact of family history on early detection of prostate cancer. Nat Med 1995; 1: 99–101.
   PubMed Web of Science ®Google Scholar
• Whittemore AS, Wu AK Kolonel LN, John EM, Gallagher RP, Howe GR, et al. Family history and prostate cancer risk in black, white and Asian men in the United States and Canada. Am J Epidemiol 1995; 141: 732–40.
   PubMed Web of Science ®Google Scholar
• Hayes RB, Liff IM, Pottem LM, Greenberg RS, Schoenberg JB, Schwartz AG, et al. Prostate cancer risk in US blacks and whites with a family history of cancer. Int J Cancer 1995; 27: 361–4.
   Web of Science ®Google Scholar
• Keetch DW, Rice JP, Suarez BK, Catalona WJ. Familial aspects of prostate cancer: a case control study. J Urol 1995; 154: 2100–2.
   PubMed Web of Science ®Google Scholar
• Lesko SM, Rosenberg L, Shapiro S. Family history and prostate cancer risk. Am J Epidemiol 1996; 144: 1041–7.
   PubMed Web of Science ®Google Scholar
• Ghadirian P, Howe GR, Hislop TG, Maisonneuve P. Family history of prostate cancer: a multi-center case-control study in Canada. Int J Cancer 1997; 70: 679–81.
   PubMed Web of Science ®Google Scholar
• Bratt O, Kristoffersson U, Lundgren R, Olsson H. The risk of malignant tumours in first-degree relatives of men with early onset prostate cancer: a population-based cohort study. Eur J Cancer 1997; 33: 2237–40.
   PubMed Web of Science ®Google Scholar
• Smith C. Heritability and concordance rates in mono-zygotic twins. Ann Hum Genet 1970; 34: 85.
   PubMed Web of Science ®Google Scholar
• Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: A study of world war II veteran twins. Prostate 1997; 33: 240–5.
   Google Scholar
• Neuhausen SL, Skolnick MH, Cannon-Albright L. Familial prostate cancer studies in Utah. Br J Urol 1997; 79: 15–20.
   Google Scholar
• Grönberg H, Wiklund F, Damber J-E. Age specific risks of familial prostate carcinoma. A basis for screening recommendation in high risk populations. Cancer 1999; 86: 477–83.
   Google Scholar
• Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh P. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367–71.
   PubMed Web of Science ®Google Scholar
• Grönberg H, Damber L, Damber JE, Iselius L. Segre-gation analysis of prostate cancer in Sweden-Support for a dominant inheritance. Am J Epidemiol 1997; 146: 552–7.
   Google Scholar
• Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, et al. A genome wide search reveals a major susceptibility locus for prostate cancer on chromosome 1. Science 1996; 274: 1371–3.
   PubMed Web of Science ®Google Scholar
• Cooney K, McCarthy J, Lange E, Huang L, Miesfeldt S, Montie J, et al. Prostate cancer susceptibility locus on chromosome lq: a confirmatory study. J Natl Cancer Inst 1997; 89: 955–9.
   PubMedGoogle Scholar
• Hsieh CL, Oakley-Girvan I, Gallagher RP, Wu AFT, Kolonel LN, The CZ, et al. Re: prostate cancer susceptibility locus on chromosome lq: a confirmatory study. J Natl Cancer Inst 1997; 89: 1893–4.
   PubMedGoogle Scholar
• McIndoe RA, Stanford JL, Gibbs M, Jarvik GP, Brandzel S, Neal CL, et al. Linkage analysis of 49 high risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25. Am J Hum Genet 1997; 61: 347–53.
   PubMed Web of Science ®Google Scholar
• Eeles RA, Durocher F, Edwards S, Teare D, Badzioch M, Hamoudi R, et al. Linkage analysis of chromosome lq markers in 136 prostate cancer families. Am J Hum Genet 1998; 62: 653–8.
   PubMed Web of Science ®Google Scholar
• Berthon P. Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998; 62: 1416–24.
   Google Scholar
• Grönberg H, Xu J, Smith JR, Carpten JD, Isaacs SD, Freije D, et al. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res 1997; 57: 4707–9.
   Google Scholar
• Grönberg H, Isaacs SD, Smith JR, Carpten JD, S BG, Freije D, et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 1997; 278: 1251–5.
   Google Scholar
• Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA. Family history of prostate cancer in patients with localized prostate cancer: an independent pre-dictor of treatment outcome. J Clin Oncol 1997; 15: 1478–80.
   Google Scholar
• Grönberg H, Smith J, Emanuelsson M, Jonsson B-A, Bergh A, Carpten J, et al. In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer. Am J Hum Genet 1999; 65: 134–40.
   Google Scholar
• Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet 1998; 20: 175–9.
   PubMed Web of Science ®Google Scholar
• Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet 1999; 64: 776–87.
   PubMed Web of Science ®Google Scholar
• Qian J, Jenkins RB, Bostwick DG. Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Eur Urol 1999; 35: 479–83.
   Google Scholar
• Zitzelberger H, Kulka U, Lehmann L, Walch A, Smith J, Aubele M, et al. Genetic heterogeneity in a prostatic carcinoma and associated intraepithelial neoplasia as demonstrated by combined use of laser-microdissec-tion, degenerate oligonucleotide primed PCR and comparative genomic hybridization. Virchows Arch 1998; 433: 297–304.
   PubMed Web of Science ®Google Scholar
• Qian JQ, Jenkins RB, Bostwick DG. Determination of gene and chromosome dosage in prostatic intraepi-thelial neoplasia and carcinoma. Anal Quant Cytol Histol 1998; 20: 373–80.
   Google Scholar
• Bartels PH, Montironi R, Hamilton PW, Thompson D, Vaught L, Bartels HG. Nuclear chromatin texture in prostatic lesions. I. PIN and adenocarcinoma. Anal Quant Cytol Histol 1998; 20: 389–96.
   PubMed Web of Science ®Google Scholar
• Bartels PH, Montironi R, Hamilton PW, Thompson D, Vaught L, Bartels HG. Nuclear chromatin texture in prostatic lesions. II. PIN and malignancy associated changes. Anal Quant Cytol Histol 1998; 20: 397–406.
   PubMed Web of Science ®Google Scholar
• Shih C, Shilo B, Goldford MP, Dannenberg S, Weinberg RA. Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci USA 1979; 76: 5714–8.
   Google Scholar
• Viola MV, Fromwitz F, Oravez S. Deb S. Finkel G, Lundy J, et al. Expression of ras oncogene p21 in prostate cancer. N Engl J Med 1986; 314: 133–7.
   Google Scholar
• Peehl DM, Wehner N, Stamey TA. Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate 1987; 10: 281–9.
   Google Scholar
• Carter BS, Epstein JI, Isaacs WB. ras Gene mutations in human prostate cancer. Cancer Res 1990; 50: 6830–2.
   PubMed Web of Science ®Google Scholar
• Cooke DB, Quarmby VE, Mickey DD, Isaacs JT, French FS. Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system. Prostate 1988; 13: 263–72.
   Google Scholar
• Stanbridge EJA. Human tumor suppressor genes. Annual Review of Genetics 1990; 24: 615–57.
   PubMed Web of Science ®Google Scholar
• Yunis JJ, Ramsay N. Retinoblastoma and subband deletion of chromosome 13. Am J Dis Childhood 1978; 132: 161–3.
   PubMedGoogle Scholar
• Friend SH, Bemards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643–6.
   PubMed Web of Science ®Google Scholar
• Benedict WF, Xu HJ, Hu SX, Takahashi R. Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 1990; 85: 988–93.
   PubMed Web of Science ®Google Scholar
• Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990; 87: 7762–6.
   PubMed Web of Science ®Google Scholar
• Mercer WE, Avignolo C, Baserga R. Role of the p53 protein in cell proliferation as studied by microinjec-tion of monoclonal antibodies. Mo Cell Biol 1984; 4: 276–81.
   Google Scholar
• Levine AJ, Momand J. Tumor suppressor genes: The p53 and retinoblastoma sensitivity genes and gene products. Biochim Biophys Acta 1990; 1032: 119–36.
   PubMed Web of Science ®Google Scholar
• Ratter V, Abutbul H, Ben-Ze'ev A. p53 transforma-tion-related protein accumulates in the nucleus of transformed fibroblasts in association with the chro-matin and is found in the cytoplasm of non-transformed fibroblasts. EMBO Journal 1983; 2: 1041–7.
   Google Scholar
• Hinds P, Finlay C, Levine AJ. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 1989; 63: 739–46.
   Google Scholar
• Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083–93.
   Google Scholar
• Foster CS, McLoughlin J, Bashir I, Abel PD. Markers of the metastatic phenotype in prostate cancer. Hum Pathol 1992; 23: 381–94.
   PubMed Web of Science ®Google Scholar
• Mottaz AE, Markwalder R, Fey MF, Klima I, Merz VW, Thalmann GN, et al. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and mol-ecular detection of p53 mutations. Prostate 1997; 31: 209–15.
   PubMed Web of Science ®Google Scholar
• Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, et al. KAI 1, a metastasis suppressor gene for prostate cancer on human chromo-some 11p11.2. Science 1995; 286: 884–6.
   Google Scholar
• Sharon N, Lis H. Lectins as cell recognition molecules. Science 1989; 246: 227–34.
   PubMed Web of Science ®Google Scholar
• Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R, et al. Automated and quantitative immuno-cytochemical assays of CD44v6 in breast carcinomas. Hum Pathol 1997; 28: 289–96.
   PubMed Web of Science ®Google Scholar
• Arch R, Wirth K, Hofmann M, Ponta H, Matzku S, Herrlich P. et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992; 257: 682–5.
   PubMed Web of Science ®Google Scholar
• Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA coding the lymphocyte homing reception CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci 1992; 89: 12160–4.
   PubMed Web of Science ®Google Scholar
• Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Gunthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994; 124: 71–82.
   PubMed Web of Science ®Google Scholar
• Terpe HJ, Stark H, Prehm P. Gunthert U. CD44 variant isoforms are preferentially expressed in basal epithelia of non-malignant human fetal and adult tissues. Histochemistry 1994; 101: 79–89.
   Google Scholar
• Sy MS, Guo YJ, Stamenkovic I. Distinct effects of two CD44 isoforms on tumour growth in vivo. J Exp Med 1991; 174: 859–66.
   Google Scholar
• Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cells 1991; 65: 13–24.
   PubMed Web of Science ®Google Scholar
• Rudy W, Hofmann R, Schwartz-Albiez R, Zoller M, Heider KH, Ponta H, et al. Two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: Each one individually suffices to confer metastatic behavior. Cancer Res 1993; 53: 1262–8.
   Google Scholar
• Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177: 443–55.
   PubMed Web of Science ®Google Scholar
• Nomura S, Willis AJ, Edwards DR, Heath JK, Hogan BEM. Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. J Cell Biol 1988; 106: 441–50.
   Google Scholar
• Brown LF, Berse B, Van De Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, et al. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial sur-faces. Mol Cell Biol 1992; 3: 1169–80.
   Google Scholar
• Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA 1986; 83: 8819–23.
   Google Scholar
• Ross FP, Chappell J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha-v-beta-3 potentiate bone resorption. J Biol Chem 1993; 268: 9901–7.
   Google Scholar
• Davies BR, Davies MPA, Gibbs FEM, Barraclough R, Rudland PS. Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell-line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. Oncogene 1993; 8: 999–1008.
   Google Scholar
• Ke Y, Jing C, Barraclough R, Smith P, Davies MPA, Foster CS. Elevated expression of calcium-binding protein p9Ka is associated with increasing malignant characteristics of rat prostate carcinoma cells. Int J Cancer 1997; 71: 832–7.
   PubMed Web of Science ®Google Scholar
• Desplan C, Heidmann O, Lillie JVV, Auffray C, Thomasset M. Sequence of rat intestinal vitamin D-dependent calcium-binding protein derived from cDNA clone evolutionary implications. J Biol Chem 1983; 258: 3502–5.
   Google Scholar
• Kuwano R, Maeda T, Usui H, Araki K, Yamakuni T, Ohshima Y, et al. Molecular-cloning of cDNA of s100-alpha subunit messenger RNA. FEBS Letters 1986; 202: 97–101.
   PubMed Web of Science ®Google Scholar
• Calabretta B, Battini R, Kraczmarek L, Deriel JK, Baserga R. Molecular-cloning of the cDNA for a growth factor-inducible gene with strong homology to S-100, a calcium-binding protein. J Biol Chem 1986; 261: 2628–32.
   Google Scholar
• Gerke V, Weber K. The regulatory chain in the p36-kd substrate complex of viral tyrosine-specific protein-kinases is related in sequence to the S-100 protein of glial-cells. EMBO Journal 1985; 4: 2917–20.
   PubMed Web of Science ®Google Scholar
• Gibbs FEM, Wilkinson MC, Rudland PS, Barraclough R. Interactions in vitro of p9Ka, the rat S-100 related, metastasis-inducing, calcium-binding protein. J Biol Chem 1994; 269: 18992–9.
   PubMed Web of Science ®Google Scholar
• Goebeler M, Roth J, Van Den Bos C, Ader G, Sorg C. Increase of calcium levels in epithelial cells induces translocation of calcium-binding proteins migration inhibitory factor-related protein 8 (MRP8) and MRP14 to keratin intermediate filaments. Biochem J 1995; 309: 419–24.
   Google Scholar
• Pechere JF. Calcium-binding proteins and calcium function. Elsevier 1977; Amsterdam.
   Google Scholar
• Van Eldik LJ, Zendegui JG, Marshak OR, Watterson DM. Calcium-binding proteins and the molecular basis of calcium action. Int Rev Cytol 1982; 77: 1–61.
   PubMedGoogle Scholar
• Hilt D, Kligman D. The S-100 protein family: a biochemical and functional overview. In: Heizmann CW, editor. Novel calcium-binding proteins: funda-mentals and clinical implications. Berlin: Springer-Verlag; 1991. p. 65–103.
   Google Scholar
• Hayle AJ, Darling DL, Taylor AR, Train D. Transfec-tion of metastatic capability with total genomic DNA from human and mouse metastatic tumor cell-lines. Differentiation 1993; 54: 177–89.
   PubMed Web of Science ®Google Scholar
• Gate CC, Belloni DR, Marin-Padilla M. Acquisition and enhanced expression of the metastatic phenotype following transfections of genomic mouse tumor DNA containing human SCLC gene sequences. Clin Exp Metastasis 1995; 13: 203–17.
   Google Scholar
• Chen H, Ke Y, Oates AO, Barraclough R, Rudland PS. Isolation of and the effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 1997; 14: 1581–8.
   Google Scholar
• Ke Y, Beesley C, Smith P, Barraclough R, Rudland P. Foster CS. Generation of metastatic variants by transfection of a nonmetastatic rat epithelial cell-line with genomic DNA from rat prostatic carcinoma cells. Br J Cancer 1997; 77: 287–96.
   Google Scholar
• Liang P. Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992; 257: 967–71.
   Google Scholar
• Blok LJ, Kumar MV, Tindall DJ. Isolation of cDNAs that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR. Prostate 1995; 26: 213–24.
   Google Scholar
• Berthon P. Cussenot O, Hopwood L, Le Duc A, Maitland NJ. Functional expression of 5V40 in normal human prostatic epithelial and fibroblastic cells: Differentiation pattern of non-tumorigenic cell lines. Int J Oncology 1995; 6: 333–43.
   Google Scholar
• Murakami YS, Brothman AR, Leach RJ, White RU. Suppression of malignant phenotype in a human prostate cancer cell-line by fragments of normal chromosomal region 17q. Cancer Res 1995; 55: 3389–94.
   PubMed Web of Science ®Google Scholar
• Ichikawa T, Ichikawa Y, Isaacs JT. Genetic factors and suppression of metastatic ability of prostatic cancer. Cancer Res 1991; 51: 3788–92.
   Google Scholar
• Bao L, Loda M, Janmey PA, Stewart R, Anand-Apte B, Zetter BR. Thymosin beta 15: A novel regulator of tumor cell motility upregulated in metastatic prostate cancer. Nature Med 1996; 2: 1322–8.
   Google Scholar
• Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371–4.
   PubMed Web of Science ®Google Scholar
• Pongracz J, Johnson GD, Crocker J, Burnett D, Lord JM. The role of protein kinase C in myeloid cell apoptosis. Biochem Soc Trans 1994; 22: 593–7.
   Google Scholar
• Lord JM, Pongracz J. Protein Kinase C: a family of isoenzymes with distinct roles in pathogenesis. J Clin Pathol: Mol Pathol 1995; 48: 57–64.
   PubMed Web of Science ®Google Scholar
• Clemens MJ, Trayner I, Meneya J. The role of protein kinase C isoenzymes in the regulation of cell proliferation and differentiation. J Cell Sci 1992; 103: 881–7.
   Google Scholar
• Freed E. A novel intergrin beta subunit is associated with the vitronectin receptor alpha-subunit (alpha-v) in a human osteosarcoma cell line and is a substrate for protein kinase C. EMBO J 1989; 8: 2955–65.
   PubMed Web of Science ®Google Scholar
• Lord JM, Ashcroft SJH. Identification and charac-terisation of Ca2+-phospholipid-dependent protein kinase in rat islets and hamster beta cells. Biochem J 1984; 219: 547–51.
   PubMed Web of Science ®Google Scholar
• Owen PJ, Johnson GD, Lord JM. Protein kinase C-delta associates with vimentin intermediate filaments in differentiated HL-60 cells. Exp Cell Res 1996; 225: 366–73.
   Google Scholar
• Berry N, Nishizuka Y. Protein kinase C and T cell activation. Eur J Biochem 1990; 189: 205–14.
   PubMedGoogle Scholar
• Evans JD, Bramhall SR, Neoptolemos JP, Eggo ME. Mechanisms of apoptosis in pancreatic cancer cell lines. Int J Pancreatol 1996.
   Google Scholar
• Mohammed RM. Bryostatin 1 induced apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk Res 1995; 19: 667–73.
   PubMed Web of Science ®Google Scholar
• Murray NR, Baumgardner GP, Burns DJ, Fields AP. Protein kinase C isotypes in human erythroleukemia (k562) cell proliferation and differentiation. Evidence that beta II protein kinase C is required for prolifera-tion. J Biol Chem 1993; 268: 15847–53.
   Google Scholar
• MacFarlane DE, Manzel L. Activation of Beta-isoenzyme of protein kinase C (PKC beta) is necessary and sufficient for phorbol ester-induced differentiation of HL60 promyelocytes. J Biol Chem 1994; 269: 4327–31.
   PubMed Web of Science ®Google Scholar
• Cacace AM, Guadagno SN, Krauss RS, Fabbro D, Weinstein IB. The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene 1993; 8: 2095–104.
   Google Scholar
• Powell CT, Fair WR, Heston WD. Differential expression of protein kinase C isoenzymes messenger RNAs in Dunning R-3327 rat prostatic tumours. Cell Growth Diff 1994; 5: 143–9.
   Google Scholar
• Comford PA, Evans JD, Dodson AR, Parsons KF, Woolfenden KA, Neoptolemos JP, et al. Protein Kinase C (PKC) isoenzyme patterns characteristically modu-lated in early prostate cancer. Am J Pathol 1999; 154: 137–44.
   PubMed Web of Science ®Google Scholar
• Sosnowski J, Stetter-Neel C, Cole D, Durham JP, Mawhinney MG. Protein kinase C mediated anti-proliferative glucocorticoid-sphinganine synergism in cultured Pollard III prostate tumour cells. J Urol 1997; 158: 269–74.
   PubMed Web of Science ®Google Scholar
• Rusnak JM, Lazo JS. Downregulation of protein kinase C suppresses induction of apoptosis in human prostatic carcinoma cells. Exp Cell Res 1996; 224: 189–99.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Berns CM, Erdos G, Carry PM. Effectiveness of isoquinolinesulfonamides on heat shock gene expression during heating at 41 degree C in human carcinoma lines. Biochem Biophys Res Commun 1994; 199: 714–9.
   PubMed Web of Science ®Google Scholar
• Herbert JM. Protein kinase C: a key factor in the regulation of tumor cell adhesion to the endothelium. Biochem Pharmacol 1993; 45: 527–37.
   PubMed Web of Science ®Google Scholar
• Blobe GC, Sachs CW, Khan WA, Fabbro D, Stabel S, Westal WC, et al. Selective regulation of expression of protein kinase C (PKC) isoenzyme in multidrug resistant MCF-7 cells-functional significance of enhanced expression of PKC-alpha. J Biol Chem 1993; 268: 658–64.
   PubMed Web of Science ®Google Scholar
• O'Brian CA, Vogel VG, Singletary SE, Ward NE. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 1989; 49: 3215–7.
   PubMed Web of Science ®Google Scholar
• Hirai M, Gamou S, Kobayashi M, Shimizu N. Lung cancer cells often express high levels of protein kinase C activity. Jpn J Cancer Res 1989; 80: 204–8.
   PubMedGoogle Scholar
• Pongracz J, Clark P, Neoptolemos JP, Lord JM. Expression of protein kinase C isoenzymes in color-ectal cancer tissue and their differential activation by different bile acids. Int J Cancer 1995; 61: 35–9.
   PubMed Web of Science ®Google Scholar
• Krongrad A, Bai G. c-fos promoter insensitivity to phorbol ester and possible role of protein kinase C in androgen-independent cancer cells. Cancer Res 1994; 54: 203–10.
   Web of Science ®Google Scholar
• Young CY, Murtha PE, Zhang J. Tumor promoting phorbol ester-induced cell death and gene expression in a human prostate adenocarcinoma cell line. Oncol Res 1994; 6: 203–10.
   Google Scholar
• Powell CT, Brittis NJ, Stec D, Hug H, Heston WD, Fair WR. Persistent membrane translocation of protein kinase C alpha during 12-0-tetradecanoylphor-bol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Diff 1996; 7: 419–28.
   PubMedGoogle Scholar
• Lamm ML, Long DD, Goodwin SM, Lee C. Trans-forming growth factor beta 1 inhibits membrane association of protein kinase C alpha in a human prostate cancer cell line, PC3. Endocrinology 1997; 138: 4657–64.
   PubMed Web of Science ®Google Scholar
• Liu B, Maher RJ, Hanun YA, Porter AT, Honn KV. 12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. Natl Can Inst 1994; 86: 1145–51.
   Google Scholar
• Powell CT, Gschwend JE, Fair WR, Brittis NJ, Stec D, Huryk R. Overexpression of protein kinase C-zeta (PKC-zeta) inhibits invasive and metastatic abilities of Dunning R-3327 MAT-LyLu rat prostate cancer cells. Cancer Res 1996; 56: 4137–41.
   PubMed Web of Science ®Google Scholar
• Morimoto RI, Tisseres A, C G Stress proteins in biology and medicine. Cold Spring Harbour: Labora-tory Press, 1990.
   Google Scholar
• Milarski KL, Welch WJ, Morimoto RI. Cell cycle-dependent association of hsp70 with specific cellular proteins. J Cell Biol 1989; 108: 413–23.
   Google Scholar
• Morimoto RI. Cells in stress: transcriptional activation of heat shock genes. Science 1993; 259: 1409–10.
   PubMed Web of Science ®Google Scholar
• Ciocca DR, Clark GM, Tandon AK, Fuqua SAN, Welch WJ, McGuire WL. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 1993; 85: 570–4.
   PubMed Web of Science ®Google Scholar
• Tomei LD, Cope FO Apoptosis: The molecular basis of cell death. Cold Spring Harbour: Laboratory Press, 1991.
   Google Scholar
• Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453–6.
   Google Scholar
• Lindquist S, Craig EA. The heat shock proteins. Annu Rev Genet 1988; 22: 631–77.
   PubMed Web of Science ®Google Scholar
• Lavoie JN, Gingras-Breton G, Tanguay RM, Landry J. Induction of Chinese hamster H5P27 gene expression in mouse cells confers resistance to heat shock. H5P27 stabilisation of the microfilament organisation. J Biol Chem 1993; 268: 3420–9.
   Google Scholar
• Arrigo AP, Suhan JP, Welch WJ. Dynamic changes in the structure and intracellular locale of the mammalian low-molecular-weight heat shock protein. Mol Cell Biol 1988; 8: 5059–71.
   Google Scholar
• Landry J, Chretien P. Laszlo A, Lambert H. Phos-phorylation of H5P27 during development and decay of thermotolerance in Chinese hamster cells. J Cell Physiol 1991; 147: 93–101.
   PubMed Web of Science ®Google Scholar
• Landry J, Lambert H, Zhou M, Lavoie JM, Hickey E, Weber LA, et al. Human H5P27 is phosphorylated as serines 78 and serines 82 by heat shock and mitogen-activated kinases that recognize the same amino acid motif as S6 kinase II. J Biol Chem 1992; 267: 794–803.
   PubMed Web of Science ®Google Scholar
• Benndorf R, Hayess K, Ryazantsev S, Wieske M, Behlke J, Lusch G. Phosphorylation and supramolecu-lar organization of murine small heat shock protein H5P25 abolish its actin polymerization-inhibiting activity. J Biol Chem 1994; 269: 20780–4.
   PubMed Web of Science ®Google Scholar
• Comford PA, Dodson AR, Parsons KF, Fordham M, Desmond AD, Woolfenden A, et al. Heat shock pro-tein (HSP) expression independently predicts clinical outcome in prostate cancer. Cancer Res 1999: Sub-mitted.
   Google Scholar